Seattle, Wash.–(BUSINESS WIRE) –January 3, 2019– Immusoft Corporation, a Seattle-Wash.-based cell therapy company, announced today it has held the final closing in its $20 million oversubscribed Series B financing. Immusoft plans to use the proceeds from this financing to advance ISP-001 (iduronicrin genleukocel-T) through Phase I/II…
SEATTLE–(BUSINESS WIRE)–Immusoft Corporation, a Seattle-Wash.-based cell therapy company, announced today that the U.S. Food and Drug Administration (FDA) has granted it Rare Pediatric Disease Designation (RPDD) for Iduronicrin genleukocel-T, Immusoft’s Sleeping Beauty transposon-engineered autologous plasmablasts for the expression and delivery of alpha-L-iduronidase (IDUA) to treat Mucopolysaccharidosis type I (MPS I).
SEATTLE–(BUSINESS WIRE)–Immusoft Corporation, a Seattle, Wash.-based cell therapy company, announced today that it has received a Phase II Small Business Innovation Research grant (SBIR) from the National Institute of General Medical Sciences, part of the National Institutes of Health (NIH). The grant, in the amount of just over $3.5 million, will enable Immusoft to further advance its modified B cell approach to treating disease.
SEATTLE–(BUSINESS WIRE)–Immusoft Corporation, a Seattle, Wash.-based gene therapy company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to treat the first indication in the company’s pipeline, MPS I (Mucopolysaccharidosis type I).
SEATTLE–(BUSINESS WIRE)–Immusoft Corporation, a Seattle, Wash.-based gene therapy company, announced today it is a winner of the Most Promising Company Award from the Precision Medicine World Conference, held in Silicon Valley last week. The award recognizes companies with especially promising and innovative health care diagnostic, therapeutic and technological solutions.
Sean Ainsworth hopes to strike biotech gold, again, joining Seattle-based Immusoft Corp. as CEO and chairman. Immusoft is a gene-therapy company that hopes to use a patient’s immune cells to treat diseases, including MPS-I, or mucopolysaccharidosis type I, a rare genetic disease that is expected to be Immusoft’s first clinical application. The company uses a cell-culture system invented by Nobel laureate David Baltimore that it calls Immune System Programming.
SEATTLE–(BUSINESS WIRE)–Immusoft Corporation, a Seattle, Wash.-based gene therapy company, announced today it has closed a $3M initial tranche of a Series B financing. The full Series B is underway. The round is expected to provide Immusoft the funding it needs to complete its Phase I/II clinical trial in MPS-I (Mucopolysaccharidoses type I) and advance its pipeline, which uses its proprietary Immune System Programming (ISP™) approach to B cell modification for treating diseases.
Immusoft is looking to get its gene therapy technology into clinical trials, and the Seattle startup announced Friday that it has raised $3 million to kickstart that process. The funding is first part of the company’s ongoing Series B…. Veteran biotech executive Sean Ainsworth is joining the company as its new CEO, filling the shoes of the company’s Founder and longtime CEO Matthew Scholz. Scholz is transitioning to become the company’s CTO and will retain his position on the board of directors.
SEATTLE, Wash. (November 1, 2016)— Immusoft Corporation, a Seattle, Wash.-based gene therapy company, has closed on $2.74 million of a $3 million fundraising round. Founders Fund’s FF Science and Technium Partners led the investment. The round was oversubscribed and Immusoft says it expects to close on the remaining amount shortly.
Immusoft has closed $2.7 million in Series A3 funding. The Seattle-based gene therapy startup developed technology that uses a patient’s immune cells to cure disease. It will use the funding to prepare for a new drug trial with the Food and Drug Administration.“The capital raised in this round will give us the resources we need to submit our Investigational New Drug application,” founder and CEO Matthew Scholz said in a news release. “We are grateful to our investors and for the speed in which we were able to close our latest effort to raise capital.”